9,620 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Carlyle Group Inc.

Carlyle Group Inc. acquired a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 9,620 shares of the company’s stock, valued at approximately $227,000. Spyre Therapeutics comprises 0.0% of Carlyle Group Inc.’s investment portfolio, making the stock its 27th largest position.

A number of other institutional investors have also recently made changes to their positions in SYRE. Quest Partners LLC purchased a new position in shares of Spyre Therapeutics in the second quarter valued at $36,000. SG Americas Securities LLC bought a new position in Spyre Therapeutics in the 2nd quarter worth about $130,000. TD Asset Management Inc purchased a new position in Spyre Therapeutics during the 2nd quarter valued at about $827,000. EFG Asset Management North America Corp. bought a new stake in shares of Spyre Therapeutics during the second quarter valued at about $869,000. Finally, Rhumbline Advisers purchased a new stake in shares of Spyre Therapeutics in the second quarter worth about $1,220,000. Hedge funds and other institutional investors own 80.39% of the company’s stock.

Spyre Therapeutics Price Performance

Shares of Spyre Therapeutics stock opened at $29.36 on Monday. Spyre Therapeutics, Inc. has a 1 year low of $8.43 and a 1 year high of $47.97. The firm has a market cap of $1.18 billion, a PE ratio of -0.41 and a beta of 2.92. The company has a 50 day simple moving average of $27.84 and a two-hundred day simple moving average of $32.05.

Spyre Therapeutics (NASDAQ:SYRE) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.04. As a group, research analysts anticipate that Spyre Therapeutics, Inc. will post -3.68 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on SYRE. Wedbush assumed coverage on shares of Spyre Therapeutics in a research note on Wednesday, September 4th. They set an “outperform” rating and a $45.00 price objective for the company. Evercore ISI initiated coverage on shares of Spyre Therapeutics in a research report on Tuesday, July 16th. They set an “outperform” rating for the company. Ten research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $43.43.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).